A double-blind comparative clinical study of amoxapine and amitriptyline in depressed, hospitalised patients.
A double blind controlled trial involving 37 inpatients whose depression was judged clinically to require antidepressant medication revealed that amoxapine and amitriptyline was approximately equal in efficacy. In average daily doses of 139.7 mg and 123 mg respectively, there seemed little difference in speed of action, or in the frequency of side effects, though amoxapine had less central nervous system stimulating consequences (tremors and restlessness) than did amitriptyline.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000639:Amitriptyline / Q000009:adverse effects / Q000627:therapeutic use*; D000657:Amoxapine / Q000009:adverse effects / Q000627:therapeutic use*; D001835:Body Weight; D002318:Cardiovascular Diseases / Q000209:etiology; D002986:Clinical Trials as Topic; D003248:Constipation / Q000209:etiology; D003866:Depressive Disorder / Q000188:drug therapy* / Q000209:etiology; D003989:Dibenzoxazepines / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D019964:Mood Disorders / Q000150:complications; D014202:Tremor / Q000209:etiology
D003989:Dibenzoxazepines; D000639:Amitriptyline; D000657:Amoxapine